Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/ijms22020740
Keywords
amyotrophic lateral sclerosis; mitophagy; mitochondria; drug target
Funding
- H2020-MSCA-ITN-2017 [765912]
- Autonomous Community of Madrid [BMD-3813]
- MCIU [PID2019105600RB-I00]
- ISCiii CIBERNED [CB18/05/00040]
Ask authors/readers for more resources
ALS is a lethal neurodegenerative disease with unknown etiology and lack of effective treatment, where most patients exhibit protein aggregation and mitochondrial accumulation. Therefore, modulators of autophagy and mitophagy may help mitigate the disease's key pathological features.
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease that usually results in respiratory paralysis in an interval of 2 to 4 years. ALS shows a multifactorial pathogenesis with an unknown etiology, and currently lacks an effective treatment. The vast majority of patients exhibit protein aggregation and a dysfunctional mitochondrial accumulation in their motoneurons. As a result, autophagy and mitophagy modulators may be interesting drug candidates that mitigate key pathological hallmarks of the disease. This work reviews the most relevant evidence that correlate mitophagy defects and ALS, and discusses the possibility of considering mitophagy as an interesting target in the search for an effective treatment for ALS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available